Accelerate Diagnostics Inc (AXDX) - Product Pipeline Analysis, 2018 Update

  • ID: 4418450
  • Company Profile
  • 37 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Becton Dickinson and Co
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corp
  • Luminex Corp
  • T2 Biosystems Inc
  • MORE
Accelerate Diagnostics Inc (Accelerate) is an in vitro diagnostics company that undertakes the development and commercialization of instrumentation for identification and testing the antibiotic susceptibility of infectious pathogens. Its product portfolio includes Accelerate Pheno system, in vitro diagnostic platform for the identification (ID) and antibiotic susceptibility testing (AST) of infectious pathogens; and Accelerate PhenoTest BC kit which provides ID and AST results for patients suspected of bacteremia or fungemia. Accelerate uses its proprietary molecular identification methods and morphokinetic cellular analysis to provide faster quantitative ID/AST results. The company has a manufacturing facility in Tucson, Arizona. Accelerate is headquartered in Tucson, Arizona, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Accelerate Diagnostics Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Becton Dickinson and Co
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corp
  • Luminex Corp
  • T2 Biosystems Inc
  • MORE
  • Accelerate Diagnostics Inc Company Overview
  • Accelerate Diagnostics Inc Company Snapshot
  • Accelerate Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Accelerate Diagnostics Inc - Pipeline Analysis Overview
  • Business Description
  • Accelerate Diagnostics Inc - Key Facts
  • Accelerate Diagnostics Inc - Major Products and Services
  • Accelerate Diagnostics Inc Pipeline Products by Development Stage
  • Accelerate Diagnostics Inc Ongoing Clinical Trials by Trial Status
  • Accelerate Diagnostics Inc Pipeline Products Overview
  • Accelerate ID/AST System - Secondary Infections
  • Accelerate ID/AST System - Secondary Infections Product Overview
  • Accelerate ID/AST System - Secondary Infections Clinical Trial
  • Accelerate ID/AST System - Wound Infections
  • Accelerate ID/AST System - Wound Infections Product Overview
  • Accelerate ID/AST System - Wound Infections Clinical Trial
  • Accelerate Pheno System - Intra-Abdominal Infections Assay
  • Accelerate Pheno System - Intra-Abdominal Infections Assay Product Overview
  • Accelerate Pheno System - Urinary Tract Infections Assay
  • Accelerate Pheno System - Urinary Tract Infections Assay Product Overview
  • Accelerate PhenoTest svBP (Bacterial Pneumonia) Kit
  • Accelerate PhenoTest svBP (Bacterial Pneumonia) Kit Product Overview
  • BAC-Xtrax System
  • BAC-Xtrax System Product Overview
  • Diagnostic Test - Antibiotic-Resistant Biothreat Agents
  • Diagnostic Test - Antibiotic-Resistant Biothreat Agents Product Overview
  • Lower Respiratory Kit
  • Lower Respiratory Kit Product Overview
  • Accelerate Diagnostics Inc - Key Competitors
  • Accelerate Diagnostics Inc - Key Employees
  • Accelerate Diagnostics Inc - Key Employee Biographies
  • Accelerate Diagnostics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Accelerate Diagnostics Inc, Recent Developments
  • Apr 21, 2018: Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018
  • Apr 12, 2018: Hampshire Hospitals NHS Foundation Trust Pioneers Use of Diagnostic Tools for Earlier Optimisation of Antibiotic Therapy for Sepsis Patients
  • Feb 15, 2018: Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
  • Jan 10, 2018: Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial pneumonia assay, doubles revenue for 2017 in Q4
  • Nov 16, 2017: Accelerate Diagnostics Welcomes Dr. Charles Watts to its Board of Directors
  • Nov 02, 2017: Accelerate Diagnostics reports Q3 2017 financial results
  • Sep 13, 2017: Plaintiffs Dismiss Class Action Appeal Against Accelerate Diagnostics
  • Aug 03, 2017: Accelerate Diagnostics Reports Q2 2017 Financial Results, Doubles Revenue Generating Placements
  • Jul 31, 2017: Accelerate Diagnostics Welcomes Dr. Romney Humphries as Chief Scientific Officer
  • May 30, 2017: Accelerate Diagnostics announces sizeable release of data at ASM Microbe 2017
  • Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • Accelerate Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Accelerate Diagnostics Inc Pipeline Products by Equipment Type
  • Accelerate Diagnostics Inc Pipeline Products by Indication
  • Accelerate Diagnostics Inc Ongoing Clinical Trials by Trial Status
  • Accelerate Diagnostics Inc, Key Facts
  • Accelerate Diagnostics Inc, Major Products and Services
  • Accelerate Diagnostics Inc Number of Pipeline Products by Development Stage
  • Accelerate Diagnostics Inc Pipeline Products Summary by Development Stage
  • Accelerate Diagnostics Inc Ongoing Clinical Trials by Trial Status
  • Accelerate Diagnostics Inc Ongoing Clinical Trials Summary
  • Accelerate ID/AST System - Secondary Infections - Product Status
  • Accelerate ID/AST System - Secondary Infections - Product Description
  • Accelerate ID/AST System - Secondary Infections - Bedside Versus Standard Microbiological Blood Culture Diagnostics: BEMIDIA Study
  • Accelerate ID/AST System - Secondary Infections - Ultra Rapid Culture Independent Detection of High-priority Carbapenem Resistant Enterobacteriaceae Directly from Blood
  • Accelerate ID/AST System - Wound Infections - Product Status
  • Accelerate ID/AST System - Wound Infections - Product Description
  • Accelerate ID/AST System - Wound Infections - Bedside Versus Standard Microbiological Blood Culture Diagnostics: BEMIDIA Study
  • Accelerate Pheno System - Intra-Abdominal Infections Assay - Product Status
  • Accelerate Pheno System - Intra-Abdominal Infections Assay - Product Description
  • Accelerate Pheno System - Urinary Tract Infections Assay - Product Status
  • Accelerate Pheno System - Urinary Tract Infections Assay - Product Description
  • Accelerate PhenoTest svBP (Bacterial Pneumonia) Kit - Product Status
  • Accelerate PhenoTest svBP (Bacterial Pneumonia) Kit - Product Description
  • BAC-Xtrax System - Product Status
  • BAC-Xtrax System - Product Description
  • Diagnostic Test - Antibiotic-Resistant Biothreat Agents - Product Status
  • Diagnostic Test - Antibiotic-Resistant Biothreat Agents - Product Description
  • Lower Respiratory Kit - Product Status
  • Lower Respiratory Kit - Product Description
  • Accelerate Diagnostics Inc, Key Employees
  • Accelerate Diagnostics Inc, Key Employee Biographies
  • Accelerate Diagnostics Inc, Subsidiaries
  • Glossary
List of Figures
  • Accelerate Diagnostics Inc Pipeline Products by Equipment Type
  • Accelerate Diagnostics Inc Pipeline Products by Development Stage
  • Accelerate Diagnostics Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Danaher Corp
  • Becton Dickinson and Co
  • Luminex Corp
  • Bruker Corporation
  • T2 Biosystems Inc
  • bioMerieux SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll